Sales growth led by walking aids, while OEM sales remained sluggish

「主力カテゴリーである歩行関連商品の受注が堅調に推移した」

「Revenue in the nursing-care and welfare equipment manufacturing and sales business for the interim consolidated accounting period exceeded the same period of the previous year, reaching ¥3,229 million, up 9.0% year on year. Repeat orders for the core walking aid product remained steady, mainly among existing customers, while replacement and additional demand expanded steadily on the back of stable operation of products already introduced. In addition, the adoption of new products progressed, increasing their contribution to revenue. Segment profit was ¥694 million, up 30.5% year on year, despite the continuing impact of higher import costs caused by the weaker yen, as improvements in production efficiency and cost-reduction measures made further progress.」

「In addition to firm repeat orders from existing customers, supported by continued use of the Company's core walking aid products, products already introduced at sales destinations have continued to operate steadily, leading to a steady increase in replacement and additional demand. As a result, sales exceeded the previous fiscal year's level, reaching ¥1,674 million, up 6.9% year on year.」

「Sales in the manufacturing and sales business for the consolidated fiscal year amounted to ¥5,730.994 million, up 0.8% year on year, as sales of the company's core walking aids and bathing-related products remained firm. Segment profit declined 4.3% year on year to ¥1,027.233 million, due to higher procurement costs resulting from the weaker yen, higher logistics costs, and temporary increases in expenses associated with the relocation of a production plant operated by an overseas subsidiary.」

「Net sales in the long-term care and welfare equipment manufacturing and sales business totaled ¥5,730 million, up 0.8% year on year, as sales of the Company's core products, including walking aids and bathing-related products, remained firm. However, segment profit declined 4.3% to ¥1,027 million due to higher procurement costs resulting from the weaker yen, soaring logistics costs, and temporary expenses associated with the relocation of an overseas subsidiary's production plant.」

「Sales in the manufacturing and sales business for the six-month interim consolidated accounting period amounted to ¥2,961 million, up 0.4% year on year. Following the temporary surge in sales of new products introduced in the previous consolidated fiscal year, and as the company's products already installed at customers' sites continued to operate well, new demand eased somewhat in the near term. Segment profit declined 13.4% year on year to ¥532 million, due to higher import costs caused by the weaker yen and depreciation of right-of-use assets and other items associated with the relocation of a production plant operated by a consolidated subsidiary.」

「Sales in the manufacturing and sales business for the six-month interim consolidated accounting period amounted to ¥2,948 million, up 2.4% year on year, as the healthcare route remained firm. Segment profit declined 6.3% year on year to ¥614 million, due to the weaker yen and higher logistics costs, among other factors.」

「The company launched the new product "Zista/Zista" in March 2024. As shipments of mobility-related products, the company's core category, remained firm, sales amounted to ¥1,725 million, down 0.9% year on year.」

「The company launched the women's rollator-type walking aid "Michelle" in September 2019, the lightweight, compact forearm-support walking aid "Citrea," designed for ease of use by women, in November 2020, the walking aid "Swarina" in October 2022, based on the concept of preventing falls during individual movements by breaking down the movements of older people in their living spaces, and the new walking aid "Zista / Zista," which does not require operation of a parking brake, in March 2024.」

「As shipments of mobility-related products, the company's core category, remained firm, sales amounted to ¥4,893 million, up 2.3% year on year.」

「Sales in the manufacturing and sales business for the six months ended 30 September amounted to ¥2,880 million, up 2.7% year on year, as sales through both the chain-store and healthcare routes remained firm. Segment profit was ¥655 million, up 75.4% year on year.」

「As shipments of mobility-related products, the company's core category, remained firm, sales amounted to ¥1,740 million, up 3.4% year on year.」

「Sales in the manufacturing and sales business for the nine months ended 31 December amounted to ¥4,243 million, compared with ¥3,858 million in the same quarter of the previous year, as sales of mobility-related products, including rollators and walking aids, remained firm through both the chain-store and healthcare routes. Segment profit was ¥642 million, up 5.1% year on year.」

「Sales in the manufacturing and sales business for the six months ended 30 September amounted to ¥2,805 million, compared with ¥2,528 million in the same quarter of the previous year, as mobility-related products, including rollators and walking aids, remained firm through both the chain-store and healthcare routes.」

「As the company's core walking aids remained firm through the healthcare route, sales amounted to ¥1,463 million, compared with ¥1,316 million in the same quarter of the previous year.」

「As demand through the chain-store route recovered and sales of walking aids, led by "Citrea," remained strong, sales amounted to ¥5,000.026 million, up 18.2% year on year. Segment profit increased 24.7% year on year to ¥683.403 million, reflecting efforts to improve operating efficiency and control fixed costs.」

「As a result, consolidated net sales for the nine months ended 31 December 2020 amounted to ¥4,389 million, up 8.5% year on year, as sales of walking aids, led by "Citrea," launched in November 2020, remained strong despite some impact from the state of emergency declaration.」

「Sales of rollators, led by Citrea, which was launched in November 2020, remained firm, resulting in revenue of ¥2,882 million, up 9.4% year on year,」

「Rollators, the Company's core products, remained firm even amid requests to refrain from going out, as they came to be recognized as daily necessities. Orders for the rollator Citrea, launched through the nursing-care channel in November 2020, also remained strong, resulting in revenue of ¥1,518 million, up 20.8% year on year,」

「Revenue in the nursing-care and welfare equipment manufacturing and sales business for the cumulative first quarter under review was ¥947 million, down 36.9% year on year, as both the chain-store and nursing-care channels remained sluggish due to requests to refrain from activities related to COVID-19. Segment profit was ¥90 million, down 52.6% year on year.」

「Revenue was ¥5,992,157 thousand, up 32.4% from the previous fiscal year, mainly because of the launch of the new women's rollator Michelle, the recovery in orders through the nursing-care channel as the impact of the voluntary product recall that occurred in the previous consolidated fiscal year subsided, the shipment of a large order for silver cars from South Korea, and the addition of sales from newly consolidated subsidiaries, among other factors.」

「Consolidated revenue for the cumulative third quarter under review was ¥4,804 million, up 34.4% year on year, mainly because of the launch of the new women's rollator, Michelle, the recovery in orders through the nursing-care channel as the impact of the voluntary product recall that occurred in the previous consolidated fiscal year subsided, the shipment of a large order for silver cars from South Korea, and the addition of sales from newly consolidated subsidiaries, among other factors,」

「In terms of profit, the gross margin declined 6.0 percentage points from the previous year, mainly because the sales mix of rollators, which have a high gross margin, declined. Gross profit after deducting the provision for returns was ¥2,083,738 thousand, down 21.6% year on year.」

「In terms of profit, the cost-of-sales ratio rose 5.5 percentage points year on year, mainly because the sales mix of rollators, which have a high gross margin, declined. Gross profit after deducting the provision for returns was ¥1,652 million, down 19.4% year on year.」

「The cost-of-sales ratio rose 6.6 percentage points, mainly because the sales mix of rollators, which have a high gross margin, declined. Gross profit after deducting the provision for returns was ¥1,094 million, down 23.5% year on year.」

「Sales of rollators, the main product category, remained strong, resulting in rollator sales of ¥1,859,856 thousand, or 134.0% of the same period of the previous fiscal year, while OEM sales were ¥669,900 thousand, or 83.4%.」

「Although OEM sales remained sluggish, sales through distributors of nursing-care and welfare equipment increased substantially, as sales of rollators, the Company's core product, remained strong, reaching ¥3,959 million.」